Spots Global Cancer Trial Database for Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

Official Title: Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma

Study ID: NCT00006119

Conditions

Brain and Central Nervous System Tumors

Interventions

hydroxyurea

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.

Detailed Description: OBJECTIVES: * Determine complete, partial, or stable response to hydroxyurea in patients with recurrent and/or nonresectable meningioma. * Determine response at 2 years to this regimen in these patients. * Determine overall and disease free survival of these patients after this regimen. * Determine quality of life of these patients. * Determine the toxicities of this regimen in these patients. OUTLINE: This is a multicenter study. Patients are stratified according to grade of disease (I vs II or III). Patients receive oral hydroxyurea daily for 2 years. Quality of life is assessed before treatment, then every 3 months for 2 years. PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study.